Drugs / anti-3-\[18F\]FACBC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01574287 | Aug 2012 → May 2019 | parathyroid gland disorder | David M. Schuster, MD | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-3-\[18F\]FACBC | “anti-3-\[18F\]FACBC is an amino acid based PET radiotracer which has shown utility in detecting a variety of tumors.” NCT01574287 ↗ |
| Known as | FACBC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01574287 ↗ |
| Modality | Diagnostic / imaging agent | “anti-3-\[18F\]FACBC is an amino acid based PET radiotracer” NCT01574287 ↗ |
| Route | Intravenous | “Drug is give intravenously over 2 minutes at time of scan” NCT01574287 ↗ |